The Prevalent Glu23Lys Polymorphism in the Potassium Inward Rectifier 6.2 (KIR6.2) Gene Is Associated With Impaired Glucagon Suppression in Response to Hyperglycemia
- Otto Tschritter,
- Michael Stumvoll,
- Fausto Machicao,
- Martin Holzwarth,
- Melanie Weisser,
- Elke Maerker,
- Anna Teigeler,
- Hans Häring and
- Andreas Fritsche
- From the Department of Endocrinology, Metabolism and Pathobiochemistry, Medizinische Klinik, Eberhard-Karls-Universität, Tübingen, Germany
Abstract
Genetic factors play an important role in the pathogenesis of type 2 diabetes. The relevance to type 2 diabetes of the common polymorphism Glu23Lys in the potassium inward rectifier 6.2 (KIR6.2) gene is still controversial. The aim of this study was to assess whether this polymorphism influences β-cell function, α-cell function, or insulin action. We therefore studied 298 nondiabetic subjects using an oral glucose tolerance test (OGTT) and 75 nondiabetic subjects using a hyperglycemic clamp (10 mmol/l) with additional glucagon-like peptide (GLP)-1 and arginine stimulation. The prevalence of the Lys allele was ∼37%, and the Lys allele was associated with higher incremental plasma glucose during the OGTT (P = 0.03, ANOVA). Neither first- nor second-phase glucose-stimulated C-peptide secretion was affected by the presence of the polymorphism; nor were maximal glucose-, GLP-1-, or arginine-induced C-peptide secretion rates; nor was insulin sensitivity (all P > 0.7). However, the relative decrease in plasma glucagon concentrations during the 10 min after the glucose challenge was reduced in carriers of the Lys allele (10 ± 3% decrease from baseline in Lys/Lys, 18 ± 2% in Glu/Lys, and 20 ± 2% in Glu/Glu; P = 0.01, ANOVA). In conclusion, our findings suggest that the common Glu23Lys polymorphism in KIR6.2 is not necessarily associated with β-cell dysfunction or insulin resistance but with diminished suppression of glucagon secretion in response to hyperglycemia. Our findings thus confirm its functional relevance for glucose metabolism in humans.
Footnotes
-
Address correspondence and reprint requests to Professor Dr. med. Hans-Ulrich Häring, Medizinische Universitätsklinik, Otfried-Müller-Str. 10, D-72076 Tübingen, Germany. E-mail: hans-ulrich.haering{at}med.uni-tuebingen.de.
Received for publication 18 January 2002 and accepted in revised form 4 June 2002.
AUCinc, incremental area under the curve; GLP, glucagon-like peptide; IGT, impaired glucose tolerance; KATP channel, ATP-sensitive K+ channel; KIR6.2, potassium inward rectifier 6.2; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; SUR1, sulfonylurea receptor; WHR, waist-to-hip ratio.
- DAIBETES














